Resources

In this blog Albert Maguire - King, Media and Communications Executive at BIA, outlines and explores BIA's revolutionary LeaP program.

A London-based biotech firm that aims to improve infant health with its research into the microbiomes of breast milk has raised £2.5 million.

Logical Biological, biospecimen and critical raw material leader based at Discovery Park, and Bcell Design, pioneers in transgenic monoclonal antibody technology, today announced a long term strategic international partnership to deliver engineered disease state materials for diagnostic and research markets.

Coulter Partners successfully completed a search assignment for the Cell and Gene Therapy Catapult (CGT Catapult) and is pleased to announce the placement of Dr. Ed Samuel as Chief Operations Officer (COO).

Discovery Park, Kent’s thriving life science and innovation community, today welcomed eight promising cardiovascular and cardiometabolic health startups to its campus. The cohort are embarking on the ‘Discovery Spark’ business growth programme, championing and supporting early stage business working on innovations in heart health.

Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its product offering, with the launch of the AAVX Total Capsid Quantification Kit and the AAV9 Total Capsid Quantification Kit.

Myricx Bio is pleased to announce the appointment of Jonathon Marks-Bluth, Ph.D., to its leadership team in the newly created position of VP, Business Development.

September has got off to a busy start at BIA, with significant raises, deals, expansion and M&A activity for members; welcoming our US counterparts to London, closely monitoring UK political shuffles and the party conference action as that kicks off with Reform and some unwelcome anti-vaccine misinformation.

The Milner Therapeutics Institute has been announced as a finalist for a 2025 OBN Award in the category of Most Impactful Industry Collaboration.

Pioneer Group has once again teamed up with global biopharmaceutical company AbbVie to launch a Golden Ticket programme designed to accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neurology, eye care, aesthetics, or other specialities including obesity, GI and hepatology.

NRG Therapeutics, an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B financing.

In this blog, Paul Nelson, Corporate Foreign Exchange at Moneycorp, outlines the unpredictability of global markets and what this means for BIA members. 

Pharmaron is thrilled to announce the successful completion of Phase One in the major expansion of our Liverpool Gene Therapy and Biologics CDMO site!

eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, has announced a new strategic partnership with Anthony Nolan: Cell Therapy & Laboratory Services (CT&LS), the experts in cellular starting materials providing donor material solutions to the cell and gene therapy industry.

MoU will explore collaborative opportunities in biomedicine, biotechnology and bioinformatics, with a strong emphasis on AI applications.

In this blog, Elisa Petris, Partner at Syncona Investment Management Limited, and Emma Johnson, Senior Investment Manager – Life Sciences at the British Business Bank, write in their capacity as Co-founders of Invest in Equity. They share why they launched the initiative, the urgency of improving gender diversity in life science investment, and how a more inclusive ecosystem can drive stronger returns and better outcomes for patients.

Arecor Therapeutics announces that it has concluded a positive Type C meeting with the US FDA for AT278 in people with both type 1 and type 2 diabetes with high daily insulin needs.

MDC and King’s College London have been awarded £400,000 funding from The Brain Tumour Charity to develop a groundbreaking new approach to treat glioblastoma, for patient benefit.

Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, has garnered widespread media attention1 this week following a renewed focus on the impact of its Brainomix 360 Stroke technology to improve recovery rates for stroke patients.